Navigation Links
Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
Date:9/1/2011

ntral nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company has nearly completed an FDA-approved Phase Ia safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depression, and anticipates initiating a Phase Ib trial in the fall. Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

For more information, please go to www.neuralstem.com.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional inf
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
2. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
3. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
4. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
5. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
6. Neuralstem Completes $5.25 Million Financing
7. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
8. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
10. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
11. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... 2015  Cypher Genomics, Inc., a leading genome ... Corporation to apply Cypher,s Coral TM technology ... patient response to innovative medicines. The information generated ... patient access to the right medicine at the ... development and potentially inform new companion diagnostics.  ...
(Date:5/20/2015)... 2015 Research and Markets ( ... "Bone Morphogenetic Proteins Market (Types : rhBMP-2 ... Oral - Maxillofacial) - Global Industry Analysis, Size, ... report to their offering. The ... on the types of recombinant BMPs, applications, and ...
(Date:5/20/2015)... Cambridge, MA (PRWEB) May 20, 2015 ... quality transporter assay services for Drug-Drug Interactions (DDI), ... Rhenovia Pharma, a world leader in assessing impact ... Quantitative Systems Pharmacology supported by biosimulation, announced today ... The agreement allows both companies to expand their ...
(Date:5/20/2015)...  HOSTING, the leading provider of managed cloud ... official partner of the College of Healthcare ... Program. This unique collaboration leverages the HOSTING ... best practices derived from the CHIME professional ... enabling member healthcare organizations to achieve and ...
Breaking Biology Technology:Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3HOSTING Named Partner of the CHIME Cooperative Member Services Program 2HOSTING Named Partner of the CHIME Cooperative Member Services Program 3
... ALS Lab Presents on Therapy Development StrategyCAMBRIDGE, Mass., ... (ALS TDI) has announced the 2009 launch of ... two-hour, interactive seminar is designed to inform and ... worldwide efforts to discover and develop effective treatments ...
... -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" ... operations in the,People,s Republic of China, today announced its ... 2009 ended December 31, 2008. , , ... -- Revenue was $32.9 million, up 24.1% ...
... potential) of stem cells and accelerates development of ... announces today the introduction of its GT(TM) Flow ... Summit to be held in New York, NY. ... validated, scalable technology for customizing the biological activity ...
Cached Biology Technology:Seminar Will Bring ALS Researchers to Patient Groups 2Seminar Will Bring ALS Researchers to Patient Groups 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 2Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 4Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 5Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 6Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 7Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 8Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 9Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 10Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 11Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 12Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 13Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 14Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 15Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 16MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 2MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 3
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... WASHINGTON, DC A new analysis by the ... that the U.S. government has spent around $430 million ... the Department of Energy funding a majority of the ... European Union and three individual European countries the ...
... of dust and pollen in the atmosphere may make your ... in clouds, Colorado State University atmospheric scientists have discovered for ... to form precipitation in clouds is linked to the abundance ... study by Paul DeMott and Anthony Prenni, research scientists in ...
... If you think of diabetes onset like an elaborate ... Jolla Institute scientist has unmasked a previously unknown cellular player, ... is a hallmark of both type 1 and type 2 ... Jolla Institute for Allergy & Immunology, who led the team, ...
Cached Biology News:Amount of dust, pollen matters for cloud precipitation, climate change 2Amount of dust, pollen matters for cloud precipitation, climate change 3La Jolla Institute scientist leads team which discovers important new player in diabetes onset 2La Jolla Institute scientist leads team which discovers important new player in diabetes onset 3La Jolla Institute scientist leads team which discovers important new player in diabetes onset 4
... offer true walk-away automation of magnetic cell separation. ... either positive or negative selection, RoboSep can label ... time. RoboSep is easily controlled via a color ... it simple and fast to set up your ...
... stabilizing 1.5mg of purified RNA samples., , ... stabilization of aqueous RNA samples that have ... guanidine, phenol/chloroform, silica, oligo dT etc or ... all the necessary components for the stabilization ...
... for stabilizing 50g of purified RNA samples for ... delivers all of the advantages and applications you ... the RNA can be used for enzymatic applications ... has been optimised for the stabilization of aqueous ...
Blasticidin resistance gene (bsr), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Biology Products: